文献速递系统性红斑狼疮

系统性红斑狼疮患者羟氯喹视网膜病变的危险因素:一项结合羟氯喹血药浓度分析的病例对照研究

Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该病例对照研究比较了23例确诊羟氯喹视网膜病变的SLE患者与547例对照,评估包括羟氯喹血药浓度在内的危险因素。多因素分析显示,累积剂量、用药时长、肌酐清除率和地理来源(西印度群岛和撒哈拉以南非洲)与视网膜病变显著相关,而羟氯喹血药浓度未显示关联。结论建议对来自上述地区、肾功能不全、用药时间长或累积剂量高的SLE患者密切监测视网膜病变。

要点

  • 羟氯喹累积剂量、用药时长、肌酐清除率降低及西印度群岛/撒哈拉以南非洲来源与视网膜病变独立相关。
  • 羟氯喹血药浓度在本研究 adherent 对照中未与视网膜病变显著关联。
  • 对高危SLE患者应密切监测羟氯喹视网膜病变。

核心结论

  • SLE患者使用羟氯喹应密切监测视网膜病变,尤其来自西印度群岛或撒哈拉以南非洲、肾功能不全、用药时间长或累积剂量高者。
  • 尽管对持续高羟氯喹血药浓度患者减少日剂量似乎合理,但本研究中血药浓度与视网膜病变无关。

研究设计与样本

  • 病例对照研究,纳入23例确诊羟氯喹视网膜病变的SLE患者(病例)和547例对照。
  • 视网膜病变定义为以下眼科检查中至少两项异常:自动视野计、频域光学相干断层扫描(SD-OCT)、多焦视网膜电图(mfERG)和眼底自发荧光。

主要发现

  • 单变量分析中,年龄(P < 0.001)、身高(P = 0.045)、肌酐清除率(P < 0.001)、血红蛋白浓度(P = 0.01)、羟氯喹用药时长(P < 0.001)、较高累积羟氯喹剂量(P < 0.001)和地理来源(西印度群岛和撒哈拉以南非洲)(P = 0.007)与视网膜病变风险相关,而羟氯喹血药浓度无关。
  • 多变量分析中,仅累积剂量(P = 0.016)、用药时长(P = 0.039)、肌酐清除率(P = 0.002)和地理来源(P < 0.0001,比值比8.7)与视网膜病变保持显著关联。

关键数值与推荐

  • 视网膜病变诊断标准:自动视野计、SD-OCT、mfERG和眼底自发荧光中至少两项异常。
  • 多变量分析中地理来源(西印度群岛和撒哈拉以南非洲)的比值比为8.7(P < 0.0001)。

临床怎么用

  • 对SLE患者使用羟氯喹时,应特别关注来自西印度群岛或撒哈拉以南非洲、肾功能不全、用药时间长或累积剂量高的患者,并密切监测视网膜病变。
  • 羟氯喹血药浓度在本研究中未显示与视网膜病变相关,不应仅凭血药浓度调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: HCQ is an essential medication in SLE, proven to lengthen survival and reduce flares. Its use, however, is limited by its rare but severe ophthalmological complications. Here, we aimed to analyse factors associated with HCQ retinopathy including HCQ blood levels. METHODS: This case-control study compared SLE patients with and without HCQ retinopathy, defined by abnormal results for at least two of the following ophthalmological tests: automated visual fields, spectral-domain optical coherence tomography (SD-OCT), multifocal electroretinogram (mfERG) and fundus autofluorescence. We compared clinical and laboratory findings to assess risk factors for HCQ retinopathy. RESULTS: The study included 23 patients with confirmed retinopathy (cases) and 547 controls. In the univariate analysis, age (P < 0.001), height (P = 0.045), creatinine clearance (P < 0.001), haemoglobin concentration (P = 0.01), duration of HCQ intake, (P < 0.001), higher cumulative HCQ dose (P < 0.001) and geographical origin (West Indies and sub-Saharan Africa) (P = 0.007) were associated with the risk of retinopathy, while HCQ blood levels were not. In the multivariate analysis, only cumulative dose (P = 0.016), duration of intake (P = 0.039), creatinine clearance (P = 0.002) and geographical origin (P < 0.0001, odds ratio 8.7) remained significantly associated with retinopathy. CONCLUSION: SLE patients on HCQ should be closely monitored for retinopathy, especially those from the West Indies or sub-Saharan Africa, or with renal insufficiency, longer HCQ intake or a high cumulative dose. Although reducing the daily dose of HCQ in patients with persistently high HCQ blood levels seems logical, these concentrations were not associated with retinopathy in this study with controls adherent to treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lenfant T, Salah S, Leroux G, et al. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatology (Oxford). 2020. PMID: 32442312. doi:10.1093/rheumatology/keaa157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。